Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report
Although lenacapavir demonstrated therapeutic potential, our case underscores the critical need to combine it with other fully active antiretroviral agents to prevent the rapid emergence of resistance and achieve long-term virological control in treatment-experienced individuals with HIV-2.
Authors
- Jeroen J. A. van Kampen (ORCID: https://orcid.org/0000-0002-7625-8230)
- Jolanda J.C. Voermans (ORCID: https://orcid.org/0000-0002-5607-7395)
- Quentin Le Hingrat (ORCID: https://orcid.org/0000-0001-9017-4941)
- Thibault Mésplède (ORCID: https://orcid.org/0000-0003-0515-9128)
- Els van Nood (ORCID: https://orcid.org/0000-0002-4962-4792)
- Rob A. Gruters (ORCID: https://orcid.org/0000-0002-8486-5903)
- Rizwan Mahmud
- Zoë Krullaars (ORCID: https://orcid.org/0000-0001-8430-0411)
- David van de Vijver (ORCID: https://orcid.org/0000-0001-5877-8526)
- Charlotte Charpentier
- Tess Voskamp
- Mike Voskamp
- Tess Nijssen
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Erasmus MC (NL)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1093/ofid/ofae705
- Citations
- 3
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases